Optimized posterior wall ablation for persistent atrial fibrillation
Official title: Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation
Run by Shanghai Chest Hospital · NCT07122336 · Data updated 2026-11-12
This study tests whether adding posterior wall ablation and electrogram-guided ablation to standard pulmonary vein isolation helps people with persistent atrial fibrillation who are having their first ablation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 384 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | July 16, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | August 14, 2025 |
| Trial ID | NCT07122336 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with symptomatic persistent atrial fibrillation lasting 7 days to 3 years, intolerant of at least one antiarrhythmic drug, and undergoing their first ablation are ideal candidates.
✕Probably not a fit
People with paroxysmal AF, long-standing persistent AF (>3 years), prior left atrial ablation, or contraindications to anticoagulation are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, controlled trial compares three approaches for first-time catheter ablation in persistent atrial fibrillation: pulmonary vein isolation (PVI) alone, PVI plus posterior wall isolation (PWI), and PVI+PWI with additional electrogram-guided (EGM) ablation. Eligible adults have symptomatic persistent AF lasting between 7 days and 3 years and have not had prior ablation. Participants are randomized to one of the three intervention groups and followed for arrhythmia recurrence and safety outcomes. The study will compare rhythm outcomes, need for repeat procedures, and procedural safety across the three arms.
Why it matters
Potential benefit: If successful, the approach could lower AF recurrence rates and reduce the need for repeat ablations, improving symptoms and quality of life.
How similar studies have gone: Previous studies of posterior wall isolation have shown mixed results and electrogram-guided ablation strategies remain experimental with limited consistent evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years 2. First-time ablation for persistent atrial fibrillation (PsAF) 3. Persistent AF definition: Sustained episodes lasting ≥7 days but ≤3 years (including episodes requiring pharmacologic or electrical cardioversion after ≥7 days) 4. Symptomatic AF with intolerance to at least one antiarrhythmic drug (AAD) 5. Documented PsAF episode: At least one recorded PsAF episode within the last 2 years prior to enrollment, confirmed by: ECG,Holter monitorin, Loop recorder, Telemetry, Transtelephonic monitoring (TTM),Implantable device 6. Ability and willingness to provide written informed consent 7. Compliance with all study follow-up requirements Exclusion Criteria: 1. Paroxysmal AF: Episodes lasting \<7 days (or requiring pharmacologic/electrical cardioversion \<7 days) 2. Long-standing persistent AF: Continuous AF duration \>3 years 3. No prior attempt/pursuit of cardioversion or sinus rhythm maintenance 4. Contraindications to systemic anticoagulation 5. Pregnancy 6. Advanced renal or hepatic failure 7. Severe valvular heart disease or cyanotic congenital heart disease 8. Hypertrophic cardiomyopathy (HCM)
Where it's running
-
Shanghai Chest Hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Mu Qin
- Email: qinmuae@163.com
- Phone: 13052320103
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FARAFLEX Mapping and Pulsed Field Ablation for Atrial Fibrillation
This trial tests the FARAFLEX Mapping and PFA System to see if it can safely help adults with drug-refractory paroxysmal or persistent atrial fibrillation.
-
Pulsed field ablation for atrial fibrillation in underrepresented minority patients
This registry will test how well Boston Scientific pulsed field ablation works and how safe it is for Black, Hispanic, Asian, and other underrepresented adults with paroxysmal or persistent atrial fibrillation.
-
Left Atrial Appendage Occlusion and Rhythm Restoration in AF Patients
This trial tests a combined procedure using the Volt PFA System and Amulet 2 to see if it safely and feasibly treats atrial fibrillation while also closing the left atrial appendage in adults with AF.
-
Qidong Yixin Granules to prevent atrial fibrillation returning after ablation
This trial tests whether taking Qidong Yixin Granules after catheter ablation can lower the chance of atrial fibrillation coming back within a year in adults with persistent AF.
-
FARAPULSE pulsed-field waveform treatment for paroxysmal and persistent atrial fibrillation
This will test new pulsed electrical waveforms delivered by the FARAPULSE PFA system to treat adults with paroxysmal or persistent atrial fibrillation.
-
PVI Alone vs PVI Plus PWI and SVCI with PFA in Persistent AF
This study tests whether adding posterior wall isolation and superior vena cava isolation to pulmonary vein isolation with pulsed-field ablation helps people with persistent atrial fibrillation stay in rhythm.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.